HPAPIs are a rapidly expanding group of therapeutics due to the recent commercial approvals of 8 ADCs and other targeted therapies. In recent years, the pharmaceutical industry has been moving towards drugs with increasing potency, including ones with OELs in the single nanograms/m3. This shift is occurring as a result of better targeted therapies in the oncology space as well as due to more toxicological data about previously approved APIs.  With much of this work being outsourced, many contract manufacturing organizations wishing to operate in this field have had to update their processes to handle these materials and ensure the safety of their operators.  In this presentation we will show how MilliporeSigma has met these challenges and ready to lead in this area moving forward.

Join our webinar to learn more about the evolution of the high potent API manufacturing industry from 10 µg to single nanogram limits, explore different safety concepts to handle highly potent compounds and expand your knowledge about the most commonly used payload classes in the ADC field.